 |
<< BACK TO SEVENTH GAVI BOARD MEETING
Seventh GAVI Board Meeting, Stockholm, 11 March 2002 8. Recommendations of the Independent Review Committee on Indonesia
Click here to download paper [MS Word, 38kb]
Discussion
- The GAVI Board had previously granted the Indonesian application for birthdose hepB vaccine conditional approval with the following two conditions:
- To provide a detailed plan of action for the proposed nation-wide expansion hepB birthdose vaccine for the first two implementing years;
- To provide plans to strengthen the function of ICC.
- After reviewing the responses and information received by Indonesia to the above conditions, the IRC recommends approval for the application for birthdose hepB vaccine for 5 years. In addition, Indonesia has made a request for injection safety support, a request that the IRC recommends be resubmitted.
- Concern was expressed regarding reports that Biopharma is experiencing high wastage rates in filling Uniject (the brand name of Biopharma's pre-filled monodose technology), which may be an indication that the technology is not completely ready for industrial use. This will need to be monitored.
DECISIONS
The Board:
8.1. Approved the recommendations of the IRC: one year of support to Indonesia for a birthdose of pre-filled monodose hepatitis B vaccine. The vaccine will be procured nationally at a price in 2002 of $0.80 per dose, at a total estimated cost for 2002 of $2,508,000, and a potential five-year commitment of $16 million. The vaccine price will be re-negotiated after one year.
<< BACK TO SEVENTH GAVI BOARD MEETING
|
|